A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
about
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trialsBTS Guidelines for the Management of Community Acquired Pneumonia in AdultsClinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials GroupSwitch over from intravenous to oral therapy: A concise overview.Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.The next generation: fluoroquinolones in the management of acute lower respiratory infection in adultsSevere pneumococcal pneumonia: impact of new quinolones on prognosis.Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studiesManagement of infections due to antibiotic-resistant Streptococcus pneumoniaePharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patientsSafety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmenAntimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.Enrofloxacin and macrolides alone or in combination with rifampicin as antimicrobial treatment in a bovine model of acute Chlamydia psittaci infection.Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community.Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study.The new fluoroquinolones: A critical reviewMycoplasma pneumoniae and its role as a human pathogen.Chronic Lyme Disease and Co-infections: Differential DiagnosisNew semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy.Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumoniaMutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinationsIn vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an In vitro dynamic modelDouble-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.Treatment for Multiple Acute Cardiopulmonary Conditions in Older Adults Hospitalized with Pneumonia, Chronic Obstructive Pulmonary Disease, or Heart Failure.Quinolone safety and efficacy more important than potency.Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.Quinolone Safety and Efficacy.Top Questions in Uncomplicated, Non-Staphylococcus aureus Bacteremia.Mycoplasma pneumoniae: A Potentially Severe Infection.Mycoplasma Pneumoniae Pneumonia: Walking Pneumonia Can Cripple the Susceptible
P2860
Q24655866-2945DCC2-2775-4865-9394-17703663BF09Q24675547-5832217F-0AC6-4281-B328-11E63E4F6A02Q28344357-755E699C-E8CA-4C9A-9BEB-263DA946A3C8Q33561813-49A376E0-AEE9-4F6E-BF82-F9958ED7D7FEQ33684318-3359FA73-CFA1-4397-9A78-07C994142FC7Q33739099-4EF97296-1B4D-4DB7-AE1B-9FC5BE889CB1Q33801878-8F19020E-E5EF-4A10-A59B-141D2F3CA279Q33846631-61AB0323-093E-414E-9129-B726BB5CA6C2Q33905858-342A90C3-1059-4E8B-A8F2-80D6F0D23045Q33975374-C46A7451-C5BF-4A93-A075-DD4DCE2323C6Q33976517-EE5FDC47-927C-444A-932E-A866B9DA695FQ33976830-D25C1E69-7F52-43C2-97FE-DFA23684E62FQ33982566-92813839-4543-4191-A590-2A4F6A3B42D3Q34107785-B47D80D8-51E5-4F1C-BCB2-BDFF998CFB89Q34108752-0D56665B-9731-42D7-A13B-C8CB2E8A562FQ34502866-24B516CA-0919-48C4-9517-1AF9F1B73B1FQ35166134-4E0C615B-9F54-4051-A3DA-A024976982EDQ35175244-BFF443F9-7E2D-4D8A-8585-FBAC9739FDBDQ35534380-94597360-29FE-4B96-9B1A-EB06FB7BE03AQ35537868-319C5F60-6A75-4BBF-836C-FAD02DD2AD02Q35649595-5AD06A11-B95E-4583-8AD9-56739793B17EQ35920629-554B2BCA-8795-4A0E-8FD3-C57DE0261DD4Q36589833-3358E294-4632-41BF-8E71-5A87B1BDB3B8Q37274639-40F178D3-6400-4B21-A546-71F6D9AFF2DEQ37612940-A7435518-BCD5-4F82-91EE-5CF66A75DD8EQ37719126-16F9A3E7-BB29-41F0-BAE3-565B49C15C8DQ37733449-CE83F07A-DBEC-480E-82FE-96474406E89AQ37878178-5B22E66B-A882-4E8D-A057-960DA8CB9D2EQ37881176-44C21294-2526-4302-8772-20D1D5529402Q39473275-6DC1F53F-C14E-418C-9379-00B4DFE57941Q39557455-661FE97A-84B7-4506-9E86-BAA348288523Q39570037-21340A38-BB2A-41FA-84E4-7732D02697C5Q42552109-A1E0FAB4-D891-443D-AF28-52D8764F3689Q42729698-6D84B337-346C-4D52-8397-2FD4E1DFBD50Q45972915-000B6C26-B8CF-4240-A6D1-D950D43BF63EQ55039125-281DA2EC-16F0-45DF-841A-0A0B650209ACQ55314495-E1D88FED-C841-4AAC-BBFA-B619625D9BF5Q58691207-39EDA8D1-9FEC-4AE0-A4CA-71229646AE75
P2860
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
A multicenter, randomized stud ...... community-acquired pneumonia.
@ast
A multicenter, randomized stud ...... community-acquired pneumonia.
@en
type
label
A multicenter, randomized stud ...... community-acquired pneumonia.
@ast
A multicenter, randomized stud ...... community-acquired pneumonia.
@en
prefLabel
A multicenter, randomized stud ...... community-acquired pneumonia.
@ast
A multicenter, randomized stud ...... community-acquired pneumonia.
@en
P2093
P2860
P1476
A multicenter, randomized stud ...... community-acquired pneumonia.
@en
P2093
R R Williams
P2860
P304
P407
P577
1997-09-01T00:00:00Z